Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628001 | 1.00 | SRC (0.66) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL880161 | 0.86 | SRC (0.60) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL24185740 | 0.83 | SRC (0.57) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL13347464 | 0.83 | SRC (0.57) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL31490482 | 0.83 | SRC (0.57) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL31692823 | 0.83 | SRC (0.48) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL3325844 | 0.83 | SRC (0.57) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL3328397 | 0.81 | SRC (0.55) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL22927432 | 0.81 | SRC (0.55) | SRCMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL718255 | 0.80 | MAPT (0.74) | SRCMAPTL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703409-A1 | LIGHT-RESPONSIVE CELL DESIGNER MOLECULE | The University of Osaka (JP) | 2026-03-04 | — | — | EP | claimed |
| WO-2024225384-A1 | LIGHT-RESPONSIVE CELL DESIGNER MOLECULE | 国立大学法人大阪大学 | 2024-10-31 | — | — | WO | claimed |
| CN-115531535-A | Compositions and methods for photochemical control of mTOR signaling and mTOR-dependent autophagy | 香港大学 | 2022-12-30 | — | — | CN | claimed |
| EP-4703409-A1 | LIGHT-RESPONSIVE CELL DESIGNER MOLECULE | The University of Osaka (JP) | 2026-03-04 | — | — | EP | disclosed |
| US-20250276994-A1 | CAP ANALOG FOR THE 5'-END OF EUKARYOTIC MESSENGER RNAS | WESTFÄLISCHE WILHELMS-UNIVERSITÄT (DE) | 2025-09-04 | — | — | US | disclosed |
| WO-2025075817-A1 | METHODS FOR SYNTHESIS OF PROTEIN HETERO-POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4533102-A2 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | The Broad Institute, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025007135-A9 | CONTROLLED GLYCAN METABOLIC ENGINEERING SYSTEMS AND APPLICATIONS THEREOF | WAYNE STATE UNIVERSITY (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025007135-A2 | CONTROLLED GLYCAN METABOLIC ENGINEERING SYSTEMS AND APPLICATIONS THEREOF | WAYNE STATE UNIVERSITY (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024225384-A1 | LIGHT-RESPONSIVE CELL DESIGNER MOLECULE | 国立大学法人大阪大学 | 2024-10-31 | — | — | WO | disclosed |
| EP-4367127-A1 | CAP ANALOG FOR THE 5'-END OF EUKARYOTIC MESSENGER RNAS | Westfälische Wilhelms-Universität Münster (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-5744305-A | Arrays of materials attached to a substrate | AFFYMETRIX, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0730663-A1 | ARRAYS OF NUCLEIC ACID PROBES ON BIOLOGICAL CHIPS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-09-11 | — | — | EP | disclosed |
| US-5489678-A | 6-NITRO-1,3-BENZOXAZOL-5-YL ALKYLOXY PROTECTIVE GROUP ON THE 5' POSITION OF A DEOXYNUCLEOSIDE; COMPUTERIZED SOLID PHASE SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (NL) | 1996-02-06 | — | — | US | disclosed |
| US-5424186-A | Biosynthesis of oligonucleotides on solid substrate by irradiation of predefined segments to remove blocking agents; then coupling with nucleotide | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-06-13 | — | — | US | disclosed |
| WO-1995011995-A1 | ARRAYS OF NUCLEIC ACID PROBES ON BIOLOGICAL CHIPS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-05-04 | — | — | WO | disclosed |
| WO-1994010128-A1 | NOVEL PHOTOREACTIVE PROTECTING GROUPS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-05-11 | — | — | WO | disclosed |
| EP-0562025-A4 | — | — | 1994-03-30 | — | — | EP | disclosed |
| EP-0562025-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010092-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276994-A1 | CAP ANALOG FOR THE 5'-END OF EUKARYOTIC MESSENGER RNAS | RNGTT, RNMT, NSUN2 | SRC 4318/4885MAPT 2751/4885L3MBTL1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.